立方制药(003020) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥256,710,773.24, a decrease of 61.39% compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2023 was ¥40,245,968.36, down 44.40% year-on-year[3] - The company reported a basic earnings per share of ¥0.26 for Q3 2023, a decrease of 44.40% year-on-year[3] - The company’s total revenue for the first nine months of 2023 was ¥1,524,501,653.00, down 19.52% from the same period in 2022[9] - Total revenue for the third quarter of 2023 was CNY 1,524,501,653, a decrease of 19.5% compared to CNY 1,894,187,478.90 in the same period last year[21] - Operating profit for the third quarter was CNY 191,331,372.50, slightly down from CNY 194,716,371.68 in the previous year[22] - Net profit for the third quarter increased to CNY 172,830,684.68, compared to CNY 170,549,504.37 in the same period last year, reflecting a growth of 1.3%[22] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥61,983,227.36, reflecting a decline of 50.19% compared to the previous year[3] - Cash flow from operating activities for the third quarter was CNY 1,455,740,368.24, down from CNY 1,789,099,393.59 in the previous year[23] - The net cash flow from operating activities for Q3 2023 was CNY 61,983,227.36, a decrease of 50.2% compared to CNY 124,439,640.14 in the same period last year[24] - The net cash flow from financing activities was CNY 44,547,060.00, a significant improvement from -CNY 46,898,267.51 in the previous year[24] - The company received CNY 360,000,000.00 from investment recoveries, a substantial increase from CNY 8,000,000.00 in the same quarter last year[24] Assets and Liabilities - The total assets as of September 30, 2023, amounted to ¥2,217,150,784.33, an increase of 4.50% from the end of the previous year[3] - As of September 30, 2023, the total current assets amounted to RMB 1,073,366,087.70, a decrease from RMB 1,452,547,083.20 at the beginning of the year[18] - The company’s total liabilities decreased significantly due to the non-consolidation of a subsidiary, impacting various financial metrics[8] - The company's total liabilities decreased to CNY 466,302,002.53 from CNY 641,534,824.26 at the start of the year, a reduction of approximately 27.4%[20] - The company's equity increased to CNY 1,750,848,781.80 as of September 30, 2023, compared to CNY 1,480,221,061.41 at the beginning of the year, representing a growth of 18.3%[20] Investments and Acquisitions - The company’s long-term equity investments increased by 990.79% to ¥157,051,879.85 due to changes in accounting methods[8] - The company acquired 51% equity in Anhui Jiufang Pharmaceutical Co., Ltd. for RMB 22,110,000, with the transaction completed during the reporting period[15] - The company’s goodwill as of September 30, 2023, was CNY 73,526,992.55, reflecting its ongoing investments and acquisitions strategy[20] Operational Metrics - The operating costs for the first nine months of 2023 were ¥815,399,383.49, a decrease of 29.85% year-on-year[9] - The company reported a decrease in total operating costs to CNY 1,357,619,917.08 from CNY 1,733,740,918.69 year-over-year, a reduction of 21.6%[21] - Research and development expenses for the third quarter were CNY 59,933,416.45, an increase from CNY 52,389,850.36 in the same period last year, indicating a growth of 14.4%[21] Inventory and Receivables - The company’s inventory decreased from RMB 361,764,867.19 to RMB 258,715,204.40 during the reporting period[18] - The company’s receivables from accounts decreased from RMB 320,921,095.92 to RMB 235,753,688.77, indicating improved collection efforts[18] - The company’s prepayments decreased from RMB 81,074,362.56 to RMB 24,234,674.00, suggesting a reduction in advance payments[18] Cash and Equivalents - The company’s cash and cash equivalents were reported at RMB 202,708,102.33 as of September 30, 2023[18] - Cash and cash equivalents at the end of Q3 2023 stood at CNY 202,708,102.33, down from CNY 268,638,205.64 at the end of Q3 2022[25] Other Information - The company received two invention patent authorizations during the reporting period, indicating ongoing innovation efforts[16] - The company did not undergo an audit for the Q3 2023 report[25]